AbbVie Stock Soars as Biotech Tops Sales Estimates, Raises Outlook

1. AbbVie reported Q4 revenue of $15.1 billion, exceeding estimates by $300 million. 2. Skyrizi and Rinvoq sales surged, offsetting Humira's 49% sales decline. 3. AbbVie raised its sales outlook for Skyrizi and Rinvoq to over $31 billion by 2027. 4. Adjusted EPS of $2.16 fell below analysts' expectations, despite revenue beat. 5. AbbVie shares jumped 8% on strong sales and positive long-term guidance.